Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy

Patients with stage 2 or 3 bowel cancer remained cancer-free nearly three years after receiving an experimental immunotherapy treatment. The trial involved 32 patients and used a drug called pembrolizumab before surgery. The results showed that none of the patients have seen a return of the disease after almost three years of follow-up.